Risk Factors for Perioperative Complications, Treatment Outcomes and Aggressive Behavior of the Tumor in Patients with Pheochromocytoma

Authors

DOI:

https://doi.org/10.15605/jafes.039.02.07

Keywords:

pheochromocytoma spells, metanephrines, perioperative complications, PASS score

Abstract

Introduction. Pheochromocytomas are catecholamine-secreting tumors arising from chromaffin cells of the adrenal gland. Surgery is the only curative treatment with a high biochemical cure rate, low mortality and high risk of perioperative complications.

Objectives. To study the demographic characteristics of patients with pheochromocytoma and to identify the risk factors for perioperative complications, treatment outcomes, and aggressive behavior of the tumor.

Methodology. We retrospectively studied the data of pheochromocytoma patients registered from 2012 to 2022.

Results. In our study, a total of 30 patients with pheochromocytoma were included. The mean age of presentation was 35 ± 12.8 years. Fifty-six percent were females, and the sex ratio was 1.3:1. Pheochromocytoma spells (60%) was the most common complaint, followed by abdominal pain (53%), orthostatic complaints (10%) and incidentalomas (6%). The baseline mean 24-hour urinary total metanephrines was 2963.7 ± 2658 mcg/24 hours, and the mean tumor size was 7.3±0.53 cm. Forty-three percent of patients underwent laparoscopic adrenalectomy, while the rest underwent open surgery. The mean Pheochromocytoma of Adrenal gland Scaled Score (PASS) was 3.41 ± 0.28, and 23% had a high risk for malignancy. Among perioperative complications, hypertensive crisis (17%) was the most common, followed by posoperative hypotension (13%), hypoglycemia (3%) and right-sided pneumothorax (3%). These patients with complications had higher metanephrine levels (5490 vs. 1880mcg/24 hours, p=0.001). Blood pressure normalized in 50%, and this was associated with male sex, younger age (29.5 vs. 40 years, p=0.03), higher metanephrines (4619 vs. 1855mcg/24 hours, p=0.001) and smaller tumors (5.91 vs. 8.61cm, p=0.046). PASS score greater than or equal to 4 was associated with higher metanephrine levels (5104 vs. 2312mcg/24 hours, p=0.021) and larger tumors (9.28 vs. 6.68 cm, p=0.024). Biochemical cure rate was achieved in 76% of patients after surgery and was associated with older age (37.7 years vs. 27.7 years, p=0.047) and absence of pheochromocytoma spells (100% vs. 61%, p=0.014).

Conclusion. Young age, smaller tumor size and higher metanephrine concentrations were associated with normalization of blood pressure post-surgery. On the other hand, older patients and those without pheochromocytoma spells had better biochemical cure rates. Patients with higher baseline metanephrine levels had increased perioperative complications. More aggressive tumor behavior was associated with higher metanephrine levels and larger tumors. Sex, baseline blood pressure and mode of surgery did not have any influence on treatment outcomes.

Downloads

Download data is not yet available.

Author Biographies

Gopinath Narayanaswamy, Gauhati Medical College and Hospital

Senior Resident, Department of Endocrinology

Debanga Sarma, Gauhati Medical College and Hospital

 Associate Professor, Department of Urology and Renal Transplant

Uma Kaimal Saikia, Gauhati Medical College and Hospital

Professor and Head, Department of Endocrinology

Abhamoni Baro, Gauhati Medical College and Hospital

Assistant Professor, Department of Endocrinology

Ashok Krishna Bhuyan, Gauhati Medical College and Hospital

Associate Professor, Department of Endocrinology

References

Pacak K, Timmers HJ, Taieb D, Lenders JWM, Eisenhofer G. Pheochromocytoma In: Robertson RP, ed. DeGroot’s textbook of Endocrinology, 8th ed. Elsevier: 2023.

Lenders JW, Duh QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. https://pubmed.ncbi.nlm.nih.gov/24893135. https://doi.org/10.1210/jc.2014-1498. Erratum in: J Clin Endocrinol Metab. 2023;108(5):e200. https://pubmed.ncbi.nlm.nih.gov/24893135. https://doi.org/10.1210/clinem/dgad064.

Lenders JWM, Kerstens MN, Amar L, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(8):1443-56. https://pubmed.ncbi.nlm.nih.gov/32412940. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486815. https://doi.org/10.1097/HJH.0000000000002438.

Ando Y, Ono Y, Sano A, Fujita N, Ono S, Tanaka Y. Clinical characteristics and outcomes of pheochromocytoma crisis: A literature review of 200 cases. J Endocrinol Invest. 2022;45(12):2313-28. https://pubmed.ncbi.nlm.nih.gov/35857218. https://doi.org/10.1007/s40618-022-01868-6.

Guerrero MA, Schreinemakers JM, Vriens MR, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209(6):727-32. https://pubmed.ncbi.nlm.nih.gov/19959041. https://doi.org/10.1016/j.jamcollsurg.2009.09.022.

Araujo-Castro M, Pascual-Corrales E, NatteroChavez L, et al. Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: A multidisciplinary approach. J Endocrinol Invest. 2021;44(12):2545-55. https://pubmed.ncbi.nlm.nih.gov/34304388. https://doi.org/10.1007/s40618-021-01649-7.

Urabe F, Kimura S, Iwatani K, al. Risk factors for perioperative hemodynamic instability in pheochromocytoma: A systematic review and meta-analysis. J Clin Med. 2021;10(19):4531. https://pubmed.ncbi.nlm.nih.gov/34640549. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509814. https://doi.org/10.3390/jcm10194531.

Bravo EL, Tagle R. Pheochromocytoma: State-of-the-art and future prospects. Endocr Rev. 2003;24(4):539-53. https://pubmed.ncbi.nlm.nih.gov/12920154. https://doi.org/10.1210/er.2002-0013.

Murphy MM, Witkowski ER, Ng SC, et al. Trends in adrenalectomy: A recent national review. Surg Endosc. 2010;24(10):2518-26. https://pubmed.ncbi.nlm.nih.gov/20336320. https://doi.org/10.1007/s00464-010-0996-z.

Azadeh N, Ramakrishna H, Bhatia NL, Charles JC, Mookadam F. Therapeutic goals in patients with pheochromocytoma: A guide to perioperative management. Ir J Med Sci. 2016;185(1):43-9. https://pubmed.ncbi.nlm.nih.gov/26650752. https://doi.org/10.1007/s11845-015-1383-5.

Akiba M, Kodama T, Ito Y, Obara T, Fujimoto Y. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg. 1990;14(3):317-24. https://pubmed.ncbi.nlm.nih.gov/2195784. https://doi.org/10.1007/BF01658514.

Mamilla D, Araque KA, Brofferio A, et al. Postoperative management in patients with pheochromocytoma and paraganglioma. Cancers (Basel). 2019;11(7):936. https://pubmed.ncbi.nlm.nih.gov/31277296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678461. https://doi.org/10.3390/cancers11070936.

Amar L, Fassnacht M, Gimenez-Roqueplo AP, et al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44(5):385-9. https://pubmed.ncbi.nlm.nih.gov/22351478. https://doi.org/10.1055/s-0031-1301339.

Granberg D, Juhlin CC, Falhammar H. Metastatic pheochromocytomas and abdominal paragangliomas. J Clin Endocrinol Metab. 2021;106(5):e1937-52. https://pubmed.ncbi.nlm.nih.gov/33462603. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063253. https://doi.org/10.1210/clinem/dgaa982.

Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551-66. https://pubmed.ncbi.nlm.nih.gov/11979086. https://doi.org/10.1097/00000478-200205000-00002.

Nölting S, Bechmann N, Taieb D, et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43(2):199-239. https://pubmed.ncbi.nlm.nih.gov/34147030. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905338. https://doi.org/10.1210/endrev/bnab019. Erratum in: Endocr Rev. 2022;43(2):440. https://pubmed.ncbi.nlm.nih.gov/34904637. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905331. https://doi.org/10.1210/endrev/bnab044. Corrigendum to: Endocr Rev. 2022 Mar 9;43(2):437-9. https://pubmed.ncbi.nlm.nih.gov/34904662. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905330. https://doi.org/10.1210/endrev/bnab045.

Young WF. Endocrine hypertension. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ. Williams textbook of Endocrinology, 14th ed. Philadelphia: Elsevier. 2020.

Downloads

Published

2024-08-05

How to Cite

Narayanaswamy, G., Sarma, D., Saikia, U. K., Baro, A., & Bhuyan, A. K. (2024). Risk Factors for Perioperative Complications, Treatment Outcomes and Aggressive Behavior of the Tumor in Patients with Pheochromocytoma. Journal of the ASEAN Federation of Endocrine Societies, 39(2), 48–53. https://doi.org/10.15605/jafes.039.02.07

Issue

Section

Original Articles